FDA Grants Accelerated Approval to Bristol-Myers Squibb’s Crazaty for Previously Treated, Locally Advanced or Metastatic Colorectal Cancer

The accelerated approval of Krazati is based on results from the Phase 1/2 KRYSTAL-1 trial, which demonstrated an objective response rate of 34% in previously treated patients with locally advanced or metastatic colorectal cancer.